Here are

Dr. Heidi Overton, the former chief of the National Institutes of Health, was sworn in as the head of the Food and Drug Administration on Thursday, after a brief Senate confirmation hearing that saw her sidestep many of the toughest questions from lawmakers. The hearing was held in the Senate wing of the Capitol, where Overton answered a handful of questions about vaccine policy and the FDA’s role in abortion‑related medical products, but avoided deeper probes into her past statements and policy positions.

The appointment matters because the FDA is the nation’s chief regulator of drugs, medical devices and vaccines. Overton’s selection follows a period of intense scrutiny over the agency’s handling of COVID‑19 vaccines and a broader debate about the FDA’s stance on abortion‑related medication. Senators from both parties have expressed concern that Overton’s past public comments on reproductive health could influence the agency’s future decisions on over‑the‑counter medication and drug approvals. The confirmation hearing was the first public test of her willingness to navigate the political and scientific pressures that have shaped the agency’s recent history.

During the hearing, senators asked Overton whether she would allow the FDA to approve a new over‑the‑counter medication that could be used for abortion, a question she answered with a vague promise to consider the agency’s scientific evidence. When pressed about her previous statements on the safety of vaccines, she reiterated the agency’s commitment to rigorous review and said she would keep the FDA’s scientific integrity at the forefront. The bipartisan group of senators who supported her nomination praised her scientific background, but a handful of lawmakers urged her to be more explicit about her positions on reproductive health products.

After the hearing, the Senate will hold a full confirmation vote on Overton’s nomination. The outcome will determine whether she can lead the FDA through a period of high public scrutiny over drug approvals, vaccine mandates and reproductive health policy. Her confirmation could set the tone for how the agency balances scientific evidence with political pressure in the coming months.